Background and Purpose: The excitatory amino acid neurotransmitter glutamate is involved in excitotoxic brain injury and neurodegeneration after cerebral ischemia. Therefore, compounds that block the release of glutamate may be useful as cerebroprotective agents. The purpose of this study was to evaluate the cerebroprotective properties of a glutamate release inhibitor, BW619C89.
T he involvement of the excitatory amino acid neurotransmitter glutamate in the neurotoxic events leading to cell death after cerebral ischemia and in various neurodegenerative disorders'-3 has prompted a plethora of investigations into the possibility of manipulating the glutamate neurotransmitter system and thereby providing protection to ischemic brain tissue.4-6 Glutamate acts on both N-methyl-Daspartate (NMDA) and non-NMDA receptor sites to elicit its neurotoxic effect, with non-NMDA receptors possibly playing a more significant role in global ischemia and NMDA receptors in focal ischemia.6-9 Antag-See Editorial Comment, page 1067 onism at either of these postsynaptic sites has proved to be an effective therapy in reducing ischemic brain injury in a number of animal models of cerebral ischemia. 6 The usefulness of an excitatory amino acid receptor antagonist as a therapy in humans, however, has been questioned recently by the discovery of undesirable behavioral and, in particular, morphological central nervous system side effects induced by the NMDA antagonist MK-801. 9, 10 The presynaptic blockade of glutamate release is an alternative approach to stroke therapy, potentially providing a more efficient intervention by preventing activation of both NMDA and non-NMDA receptor sites. Recently, the glutamate release inhibitor BW1003C87
[2,4-diamino-5-(2,3,5,-trichlorophenyl)pyrimidine] has been reported to protect against both global and focal ischemia in the rat.81' BW1003C87 is unsuitable for development because it has antifolate properties, potently inhibiting the enzyme dihydrofolate reductase. In the study reported here, a structural analogue of BW1003C87 devoid of antifolate activity, BW619C89 [4-amino-2-(4-methyl-1-piperazinyl)- 5 The effect of BW619C89 on 3H-y-aminobutyric acid (GABA) and 3H-acetylcholine release from prelabeled brain slices was determined using previously described methods and a Brandel continuous superfusion system with sample collection every 5 minutes.12"3 Slices of rat brain cortex were incubated for 30 minutes at 37°C either in 10 'H-CGS 19755 (NMDA, rat cortex); 3H-a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA, rat cerebral cortex); 3H-cyclopentyl 1,3-dipropylxanthine (adenosine A,, whole rat brain); 3H-CGS 21680 (adenosine A2, rat striatum); 3H-thienylcyclohexyl piperidine (phencyclidine, rat cerebral cortex); and 3H-platelet activating factor (rabbit platelets).
The method used for MCA occlusion was essentially as described by Tamura et 5, 10 , and 20 mg/kg. All solutions were infused at a rate of 0.5 mL/min. Blood pressure and heart rate were monitored for 30 minutes after administration. All wounds were then sutured, artificial ventilation was withdrawn, and the animal was allowed to recover while breathing oxygen-enriched air. When mobility returned (usually within 45 minutes), the rat was returned to a cage with access to food and water.
After 48 hours, the rats were reanesthetized with pentobarbitone (60 mg/kg IP), a needle was inserted into the left ventricle of the heart, and heparinized saline was perfused at a pressure of 120 mm Hg. When effluent from the incised right atrium was bloodless, the saline perfusion was stopped, the incised right atrium clamped, and 100 mL of 4% triphenyltetrazolium chloride in saline infused through the left ventricle. After 5 minutes, the right atrium was unclamped, the perfusate drained, and the animals perfusion-fixed with 20 mL of 10% formalin in saline. The brain was removed and stored in formalin. Infarct size was determined (usually in 12 sections, starting at 5.00 mm anterior to the bregma and continuing through to 6.00 mm posterior to the bregma according to the atlas of Pellegrino and Cushman5) using an IBAS 2000 image analyzer (Kontron Electroniks, Watford, England). Areas of both left and right cortex and basal ganglia regions were measured. Some infarcted tissue tended to be badly fixed, which rendered it difficult to handle, resulting in areas of dead tissue missing from the section. In these cases, the infarct area was reconstructed on the image analyzer using the hemispheric contour.
Some edema was usually present in the area of infarct in the left hand hemisphere. To Doses of BW619C89 (10 to 40 mg/kg IV) produced markedly significant reductions in both cortical and total brain infarct volume (Table 5 ) with a 43% reduction of total infarct volume at 10 mg/kg (P<.01); 57% at 20 mg/kg (P<.001), and a maximum reduction of total infarct volume of 62% at 30 mg/kg (P<.001). The dose-response relation for preservation of total (cerebral cortex plus basal ganglia regions) infarct volume appeared to be bell-shaped, with diminished but signif- (7%), A2 (8%), phencyclidine (20%), and platelet activating factor (34%) binding sites. The site of action of BW619C89 is still under investigation, but like the chemically related analogues BW1003C878 and lamotrigine,12 BW619C89 inhibited veratrine-but not potassium-stimulated glutamate release, suggesting an action at voltagegated sodium channels (also see Reference 17 for further discussion).
The rat MCA occlusion model of focal ischemia involves irreversible occlusion of a blood vessel supplying both the cerebral cortex and deeper brain structures.14 The Fischer 344 strain of rat used in this study is considered the normotensive rat strain of choice, with MCA occlusion producing a large and consistent infarct. 16 Only at the highest dose of BW619C89 (40 mg/kg) was there any indication of a bell-shaped dose-response relation when total (cortex and basal ganglia) infarct volume was-assessed. Subsequent analysis of the cortical and noncortical infarct volumes revealed, however, that there was a significant sparing of noncortical tissue damage at doses of BW619C89 of 20 and 30 mg/kg, suggesting that a proportion of the basal ganglia region is not beyond salvage. However, this effect of BW619C89 on the tissue containing the ischemic core has not previously been observed for BW1003C87, using both histological assessment and 2-deoxyglucose measurements." Whether this reflects pharmacokinetic differences between the compounds is unclear but may relate to BW619C89 having a far higher brain-plasma partition ratio (greater than 30) compared with BW1003C87 (brain-plasma ratio, 3 to 4; Salmon J. 1993. Unpublished data), which may influence rapid drug distribution in ischemic tissue with a compromised blood supply. In the rat, BW619C89 has a plasma and brain half-life of 4 
